louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00606827: Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy
Official title: Sodium Bicarbonate Versus Saline for the Prevention of Contrast-induced Nephropathy in Patients Undergoing Coronary Angiography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Contrast-Induced Nephropathy
Keywords: Contrast-induced nephrophaty
Contrast media
Angiography
Coronary percutaneous intervention
Lead sponsor: Ospedale Misericordia e Dolce
Sponsor class: OTHER
First posted: 2008-02-05
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Contrast-induced nephrophaty (CIN) accounts for more than 10% of hospital-acquired renal failure. Hydration with sodium bicarbonate is more protective than isotonic saline in animals. Limited data are available in humans. We compared the efficacy of sodium bicarbonate versus isotonic saline to prevent CIN in a large population of patients with renal dysfunction undergoing coronary angiography or intervention.


Eligibility criteria: Inclusion Criteria:

* patients with creatinine clearance \< 60 mL/min

Exclusion Criteria:

* contrast medium administration within the previous 10 days
* end-stage renal failure requiring dialysis
* refusal to give informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Prato
country: Italy
facility: Ospedale Misericordia e Dolce
Study officials:
affiliation: Cardiology Unit - Prato
name: Mauro Maioli, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Maioli M, Toso A, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Bellandi F. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol. 2008 Aug 19;52(8):599-604. doi: 10.1016/j.jacc.2008.05.026.
Clinical trial NCT06918327: Effect of CGF on Postoperative Pain After Third Molar Surgery
Official title: The Power of Concentrated Growth Factor: A New Era in Pain Management in Third Molar Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oral Complication
Keywords: Pain
Third molar
VAS scale
Lead sponsor: Ege University
Sponsor class: OTHER
First posted: 2025-04-09
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effects of concentrated growth factor (CGF) on pain after bilateral impacted third molar surgery and to determine its contribution to the healing process.

The main question it aims to answer is:

Is CGF effective on reducing the pain in impacted third molar surgery? Researchers compare the pain on the CGF-applied and CGF free sides after impacted third molar surgery. Postoperative pain is assessed using the Visual Analogue Scale. TThe postoperative outcomes including pain are clinically assessed at different-time intervals (1-7 days).


Eligibility criteria: Inclusion Criteria:

* Patients with bilateral, symmetrical, bone-retained (vertical, mesioangular, horizontal) impacted wisdom teeth in the mandible, regardless of gender
* Patients without any systemic disease
* Patients who have been informed about the duration, purpose and requirements of the study and who have signed the informed consent form voluntarily.

Exclusion Criteria:

* Having a disease affecting general health that requires the application of prophylactic antimicrobial agents
* Having a systemic viral, fungal or bacterial infection
* Patients with acute or chronic maxillary sinusitis
* Suspected or diagnosed pregnancy and nursing mothers
* Patients with heart and vascular diseases
* Patients with liver disease, haematological disease and neoplastic disease
* Patients who have recently received anti-inflammatory therapy
* Patients with chronic medication use (antihistamines, NSAIDs, steroids and antidepressants)
* Patients predisposed to psychotic or psychopathic tendencies
* Patients with rheumatic diseases, blood diseases, diabetes mellitus
* Patients at cardiological risk of infective endocarditis
* Patients under antibiotic pressure

Primary outcomes:
measure: Postoperative pain on CGF-applied and CGF free sides in bilateral impacted third molar surgery
timeFrame: The postoperative outcomes including pain are clinically assessed at different-time intervals (1st, 2nd, 3rd, 4th, 5th, 6th and 7th days).
Secondary outcomes:
Other outcomes:
Locations:
city: Izmir
country: Turkey
facility: Ege University Faculty of Dentistry
state: Bornova
Study officials:
affiliation: Ege University
name: Mert Zeytinoğlu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05198427: mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients.
Official title: Study MOTIF : mTOR Inhibitors: the Lesions Induced by Papillomavirus for Transplant Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Transplantation Organ
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2022-01-20
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient transplanted with HPV-induced lesions from the DIVAT (Validated Transplantation Computerized Data) database for patients followed at the hospital Edouard Herriot

Brief summary: The injuries induced by Human Papillomavirus (HPV) (anogenital condyloma mainly) are more frequent among transplanted patients due to their immunosuppression. These injuries are benign but they have a negative impact on the patients' quality of life. The initial treatment is topical and then surgical. The injuries can relapse, especially among transplanted patients.

The modification of the immunosuppressant treatment with a switch to mTOR inhibitors (mammalian Target Of Rapamycin) has shown its efficacy in preventing the recurrence of squamous cell carcinomas or treating Kaposi's disease.

By analogy, this therapeutic strategy can be sometimes put forward to transplanted patients with HPV-induced injuries.

The principal objective of this study is to describe the evolution of HPV-induced lesions in solid organ transplant patients.


Eligibility criteria: Inclusion Criteria:

* Adult patient (Age ≥ 18 years)
* Transplanted patient (any organ), having developed HPV-induced lesions after transplantation
* Patient followed or having been followed at Edouard Herriot Hospital (HEH)
* Patient having been informed and not having objected to participating in the study

Exclusion Criteria:

* Transplanted patient without HPV-induced lesions

Primary outcomes:
measure: Evolution of HPV related lesions in patient with switch
timeFrame: at inclusion
measure: Evolution of HPV related lesions in patient without switch
timeFrame: at inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital Edouard Herriot
state: Rhône-Alpes
Study officials:
affiliation: Hôpital Rdouard Herriot
name: Fanny BURON, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00716027: Applying Social Comparison Theory to Behavioral Weight Loss: Does Modifying Group Membership Improve Outcome?
Official title: Applying Social Comparison Theory to Behavioral Weight Loss: Does Modifying Group Membership Improve Outcome?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: The Miriam Hospital
Sponsor class: OTHER
First posted: 2008-07-16
Enrollment: 80
Sex: ALL
Minimum age (years): 21
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether a modified behavioral treatment for weight loss that includes one-on-one treatment for individuals struggling to lose weight is associated with more weight loss than a standard behavioral treatment.


Eligibility criteria: Inclusion Criteria:

* BMI between 27 and 45 kg/m2

Exclusion Criteria:

* participating in a weight loss program or taking a weight loss medication
* currently pregnant, lactating, or less than 6-months post-partum or plan to become pregnant during the time of the intervention.
* report a heart condition, chest pain during periods of activity or rest, or loss of consciousness
* report conditions that would render the participant unlikely to follow the study protocol (e.g., terminal illness, relocation, substance abuse, sever psychiatric condition, dementia).

Primary outcomes:
measure: weight
timeFrame: weekly for 24-weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Providence
country: United States
facility: The Miriam Hospital
state: Rhode Island
Study officials:
affiliation: The Miriam Hospital
name: Rena R Wing, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04145427: Impact of a LCD on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant Patients
Official title: Impact of a Low Carbohydrate Diet (LCD) on Metabolic Inflexibility and Cardiovascular Risk in Liver Transplant (LT) Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Weight Gain
Keywords: Liver Transplant, Low Carbohydrate Diet
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
First posted: 2019-10-30
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is looking to see how a 6-month low carbohydrate diet can affect the body's ability to use energy in addition to the affects it has on the heart and blood vessel health.

Detailed description: Weight gain often occurs following a liver transplant. This weight gain is problematic as it leads to many other health problems. The reasons of this weight gain are still poorly understood. To better understand weight gain, this study is looking to see how a 6-month low carbohydrate diet can affect the body's ability to use energy in addition to the affects it has on heart and blood vessel health.

This study will help researchers to better understand weight gain after a transplant. This knowledge will help doctors prevent weight gain after a liver transplant and therefore improve the health of liver transplant patients.

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* At least 12 months after LT
* Obese (BMI \> 30kg/m2)

Exclusion Criteria:

* Acute cellular or chronic rejection within 3 months
* Post-LT liver or non-liver related malignancy
* Active viral hepatitis (B or C), autoimmune hepatitis
* Untreated biliary strictures or vascular complications (i.e. hepatic artery thrombosis)
* Poorly controlled Diabetes mellitus
* Relapse of alcohol abuse after LT
* Stage 5 Chronic Kidney Disease
* Current pregnancy

Primary outcomes:
measure: Change in weight
timeFrame: baseline to 6 months
Secondary outcomes:
measure: Change in metabolic flexibility
timeFrame: baseline to 6 months
measure: Change in LDL-C
timeFrame: baseline to 6 months
measure: Change in total cholesterol
timeFrame: baseline to 6 months
measure: Change in small dense low-density lipoprotein
timeFrame: baseline to 6 months
measure: Change in adiposity
timeFrame: baseline to 6 months
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
Study officials:
affiliation: Virginia Commonwealth University
name: Mohammad Siddiqui, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01696227: Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children
Official title: Targeted Pathogen Replacement With Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Recurrent UTIs
Catheter-Related Infections
Keywords: Nissle 1917
Probiotic
Uropathogen
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
Collaborators: name: Thrasher Research Fund
First posted: 2012-09-28
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with urinary catheters that will be getting them removed

Brief summary: Background:

Urinary tract infections (UTIs) are a common and costly cause of doctor visits for children. Frequent UTIs trigger kidney damage that leads to serious diseases like high blood pressure, pregnancy complications, and kidney failure. Treating UTIs with preventative antibiotics has not shown improvement of the risk of these diseases, and contributes to the growing public health issue of antibiotic resistant bacteria. Bacteria that cause UTIs originate from the bowel. In an effort to reduce the number of UTIs, investigators want to exchange the bacteria living in our bowels for a more harmless variety.

Hypothesis and specific aims:

Investigators hypothesize a probiotic comprised of a probiotic bacteria will change the bowel bacteria, thereby reducing the numbers of infection-causing bacteria, thus reducing frequency of UTIs in healthy patients with recurrent UTIs and those patients with urinary tract problems that require use of catheters to empty their bladders.

Aim 1: Investigators plan to challenge infection-causing bacteria like Pseudomonas species, Enterococcus species, and Klebsiella species to live in the same environment with the probiotic bacteria to see how the numbers of each bacteria change.

Aim 2: Investigators will culture bacteria that live on urinary catheters and then challenge them to live in the same environment as the probiotic bacteria.

Potential Impact:

This novel treatment prevents UTIs by exchanging a patient's bowel bacteria for a harmless bacteria and reduces the use of antibiotics overall in the community.


Eligibility criteria: Inclusion Criteria:

* Patients with urinary catheters placed that will be getting them removed

Exclusion Criteria:

* Patient's currently getting treated for UTI

Primary outcomes:
measure: Ability of Nissle 1917 to adversely affect the growth in vitro of identified uropathogens
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
affiliation: Nationwide Children's Hospital
name: Elizabeth J Lucas, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01661127: Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis
Official title: Phase 0 Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Psoriasis
Metabolic Syndrome
Depression
Lead sponsor: Pusan National University Hospital
Sponsor class: OTHER
First posted: 2012-08-09
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of diagnosed with psoriasis in Pusan National University Hospital

Brief summary: Psoriasis is associated with increases in markers of inflammation in the skin and blood and increasingly is thought to be a systemic inflammatory disease and risk factor for incident diabetes mellitus, myocardial infarction, stroke, and premature cardiovascular death. Furthermore, it is important for clinicians to be aware that psoriasis can have a substantial emotional impact on an individual, which is not necessarily related to the extent of skin disease.

FDG-PET/CT represents an innovative approach to studying systemic inflammation in a manner that is sensitive, quantifiable, and anatomically localizable. Also, recent study show that chronic disease such as end stage renal disease with depressive symptoms have decreased cerebral glucose metabolism in several brain areas in F-18-FDG PET/CT. So this protocol was designed to evaluate usefulness of PET/CT to detect systemic inflammation and abnormality of cerebral glucose metabolism and association with metabolic syndrome/major depressive symptoms in patients with psoriasis.

Detailed description: 10 Patients with psoriasis

1. Evaluate PASI score
2. Evaluate comorbidity with metabolic syndrome

   * Body mass index(BMI)
   * Checking blood pressure
   * Checking blood sugar
   * Smoking and drinking history
   * Checking blood cholesterol level
   * Risk factors of cardiovascular disease
3. PET/CT for measuring the extent and site of psoriasis with inflammation

Eligibility criteria: Inclusion Criteria:

* Histological diagnosis of plaque type psoriasis
* at least 18 years old

Exclusion Criteria:

* those who cannot understand questionnaire
* those who take antidepressant

Primary outcomes:
measure: Beck depression inventory scoring and Korean Hamilton depression scale scoring
timeFrame: Day 0 and 28 weeks later
Secondary outcomes:
measure: Brain glucose uptake using PET/CT
timeFrame: Day 0 and 28 weeks later
Other outcomes:
Locations:
city: Busan
country: Korea, Republic of
facility: Department of dermatology, Pusan National University Hospital
Study officials:
affiliation: Pusan National University Hospital
name: Byung-Soo Kim, Ph D.
role: STUDY_CHAIR
References:
Clinical trial NCT00609427: Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study
Official title: Effects of Cognitive Intervention for Older Adults With Memory Decline: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Mild Cognitive Impairment
Keywords: cognitive training
cognitive rehabilitation
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
First posted: 2008-02-07
Enrollment: 30
Sex: ALL
Minimum age (years): 65
Maximum age (years): 90
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the effects of training in memory skills vs. use of external memory aids on everyday memory functioning in older people with mild cognitive impairment.

Detailed description: Some older people experience memory loss that is worse than other people of their age, although they are not demented. This condition is known as mild cognitive impairment (MCI). Healthy older people can learn mnemonic strategies to improve their memory abilities. Can cognitive rehabilitation help people with MCI do better on mental tasks or maintain better functioning in everyday life? This study will evaluate the effects of two different rehabilitation programmes. Patients in the memory training group will learn mental strategies aimed at improving memory. Patients in the memory compensation group will learn to use external memory aids.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of mild cognitive impairment

Exclusion Criteria:

* Unable to speak and understand English
* Unable to comply with treatment program due to significant comorbid illness; OR
* Anticipated inability to attend all study sessions

Primary outcomes:
measure: Rey Auditory Verbal Learning Test
timeFrame: 19-20 weeks
measure: Wechsler Memory Scale - Logical Memory
timeFrame: 19-20 weeks
measure: Face-name associations test
timeFrame: 19-20 weeks
measure: Multifactorial Memory Questionnaire - Ability subscale
timeFrame: 19-20 weeks
Secondary outcomes:
measure: Rivermead Behavioural Memory Test
timeFrame: 19-20 weeks
measure: FAS test (non-memory)
timeFrame: 19-20 weeks
measure: Category fluency (non-memory test)
timeFrame: 19-20 weeks
measure: Victoria Stroop Test (non-memory test)
timeFrame: 19-20 weeks
measure: Digit Span (non-memory test)
timeFrame: 19-20 weeks
measure: Multifactorial Memory Questionnaire - Strategies and Contentment subscales
timeFrame: 19-20 weeks
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: McGill University Health Centre
state: Quebec
Study officials:
affiliation: Research Institute of the McGill University Health Centre
name: Lisa Koski, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00478127: Hepatocyte Growth Factor and Cardiovascular Autonomic Function
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type-2 Diabetes
Lead sponsor: Oita Red Cross Hospital
Sponsor class: OTHER
First posted: 2007-05-24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Time perspective: OTHER

Brief summary: In this study, we tested the hypothesis that elevated HGF is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients not receiving insulin treatment.


Eligibility criteria: Inclusion Criteria:

* Type-2 diabetes

Exclusion Criteria:

* Type-1 diabetes

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Oita Red Cross Hospital
name: Futoshi Anan
role: PRINCIPAL_INVESTIGATOR
References: